HUTCHMED (NASDAQ:HCM) Downgraded to Hold Rating by Wall Street Zen

HUTCHMED (NASDAQ:HCM) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued on Saturday.

Other equities analysts also recently issued research reports about the company. Weiss Ratings restated a “hold (c)” rating on shares of HUTCHMED in a report on Thursday, January 22nd. Jefferies Financial Group raised shares of HUTCHMED to a “strong-buy” rating in a research report on Monday, January 19th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, HUTCHMED currently has a consensus rating of “Hold” and an average price target of $20.88.

HUTCHMED Stock Performance

Shares of NASDAQ:HCM opened at $13.85 on Friday. The stock’s 50-day moving average is $14.71 and its 200 day moving average is $14.97. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.51 and a current ratio of 4.65. HUTCHMED has a 1 year low of $11.51 and a 1 year high of $19.50.

HUTCHMED (NASDAQ:HCM) last released its quarterly earnings data on Thursday, March 5th. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $2.50 by ($2.49). The business had revenue of $135.42 million during the quarter, compared to analyst estimates of $290.50 million. On average, analysts anticipate that HUTCHMED will post 0.16 EPS for the current fiscal year.

Institutional Trading of HUTCHMED

Hedge funds have recently modified their holdings of the business. Goldman Sachs Group Inc. grew its position in shares of HUTCHMED by 8.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 93,919 shares of the company’s stock worth $1,413,000 after buying an additional 7,342 shares during the period. Jane Street Group LLC lifted its position in HUTCHMED by 128.0% during the 1st quarter. Jane Street Group LLC now owns 222,241 shares of the company’s stock valued at $3,343,000 after acquiring an additional 124,771 shares during the period. M&G PLC boosted its stake in HUTCHMED by 0.4% during the second quarter. M&G PLC now owns 259,617 shares of the company’s stock worth $3,894,000 after acquiring an additional 924 shares in the last quarter. ABN Amro Investment Solutions bought a new stake in HUTCHMED during the second quarter worth about $962,000. Finally, Tema Etfs LLC purchased a new stake in HUTCHMED in the second quarter worth about $641,000. Institutional investors own 8.82% of the company’s stock.

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.